Introduction
Percutaneous catheter ablation has become an important therapeutic option for treating patients with atrial fibrillation (AF) [1] . AF catheter ablation generally requires multiple sheaths inserted into a single femoral vein in order to introduce ablation and mapping catheters into the atria, and has a potential risk for the occurrence of venous thromboembolisms (VTEs) after the ablation. Periprocedural VTEs are a rare occurrence but a critical complication of AF ablation [2] . Adequate periprocedural anticoagulation using oral anticoagulants plays an important role in preventing thromboembolic complications associated with AF ablation [3, 4] . Direct oral anticoagulants (DOACs) have been widely used for periprocedural anticoagulation management in AF ablation [5, 6] . So far limited data are available on the incidence of VTEs after AF ablation among patients receiving periprocedural anticoagulation with DOACs. The present study aimed to investigate the incidence of symptomatic deep vein thromboses (DVTs) and pulmonary thromboembolisms(PTEs) among patients who underwent catheter ablation of AF and received periprocedural DOAC treatment.
Methods

Study Population
This retrospective observational study enrolled 2,193 consecutive AF patients who received periprocedural oral anticoagulation with DOACs prior to AF catheter ablation at Gunma Prefectural Cardiovascular Center between April 2011 and April 2018. All patients underwent transthoracic echocardiography to evaluate the atrial and ventricular sizes and left ventricular function using standard parasternal and apical views before the procedure, and transesophageal echocardiography to rule out any intracardiac thrombi on the day of the procedure or the day before. Written informed consent for the electrophysiological study and catheter ablation of AF was obtained www.jafib.com
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Abstract
Background: Periprocedural venous thromboembolisms (VTEs) are a rare occurrence but a critical complication after catheter ablation of atrial fibrillation (AF). The aim of this study was to investigate the incidence of symptomatic deep vein thromboses (DVTs) and pulmonary thromboembolisms (PTEs) in patients who underwent AF catheter ablation and received periprocedural oral anticoagulation with direct oral anticoagulants (DOACs).
Methods and Results: A total of 2,193 consecutive patients undergoing AF catheter ablation with periprocedural DOACs were retrospectively analyzed.Two patients (0.091%) experienced symptomatic DVTs after the ablation, and no patients had any PTEs. One patient was a 72-year-old female who underwent cryoballoon ablation with periprocedural apixaban at a dose of 2.5 mg twice daily. The other patient was a 74-year-old male who underwent a HotBalloon ablation and thereafter radiofrequency catheter ablation for recurrent AF with edoxaban at 30 mg once daily. Both DVT patients underwent AF ablation by the right femoral vein approach, and after discharge had right leg pain and swelling on post-procedural days 4 and 8, respectively. The DVT was treated by increasing the dose of apixaban and changing it from 30 mg/ day of edoxaban to 15-30 mg/day of rivaroxaban, and the thrombi completely disappeared in both patients without any thromboembolic and hemorrhagic complications.
Conclusions: AF catheter ablation with periprocedural DOAC treatment revealed an extremely low incidence of symptomatic VTEs, which may be successfully treated by increasing the DOAC dose or changing the DOAC type.
Original Research from all patients.
Periprocedural Anticoagulation
Periprocedural oral anticoagulation was performed with the standard or reduced DOAC dosage approved in Japan: dabigatran at a dose of 110 or 150 mg twice daily, rivaroxaban at 10 or 15 mg once daily in the morning, apixaban at 2.5 or 5 mg twice daily, or edoxaban at 30 or 60 mg once daily in the morning.
The reduced dosage of the DOACs was used according to the dose reduction criteria of each DOAC: age ≥70 years, creatinine clearance (CCr) of 30-50mL/min, history of gastrointestinal bleeding, or concomitant treatment with potent P-glycoprotein inhibitors in dabigatran patients; CCr of 15-50 mL/min in rivaroxaban patients; at least 2/3 of the following indices (age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL) in apixaban patients; and body weight ≤60 kg, CCr of 15-50 mL/min, or concomitant treatment with potent P-glycoprotein inhibitors in edoxaban patients.
All patients received oral anticoagulation for more than one week before the ablation procedure; most of the patients received that for more than one month. The DOACs were continued throughout the periprocedural period, or discontinued only on the day of the procedure and reinitiated on the next morning after the procedure [7, 8] .
Immediately after the femoral venous puncture, a heparin bolus of 5,000-10,000 units was administered intravenously, followed by a continuous and additional bolus heparin infusion to maintain an activated clotting time (ACT) between 300 and 400 seconds. The ACT was measured every 10 minutes until the ACT value reached 300 seconds and thereafter every 10-30 minutes. The intravenous heparin administration was once stopped at the end of the procedure, and protamine was administered to partially reverse the anticoagulation effects of heparin at the operator's discretion. The venous sheaths for the ablation were removed, and hemostasis of the femoral venous puncture sites was achieved by manual compression for at least five minutes or figure-of-eight sutures [9, 10] . All patients underwent bed rest for eight hours to maintain hemostasis, and received a continuous infusion of unfractionated heparin at a dose of 10,000 units per 24 hours until the DOACs were administered on the next morning after the procedure. Post-ablation oral anticoagulation was continued for at least three months.
Catheter Ablation
The catheter ablation procedures have been previously described in detail [7, 8] . All patients were kept under deep conscious sedation throughout the procedure, using propofol or dexmedetomidine and pentazocine.
The ablation strategy using an open-irrigated radiofrequency ablation catheter consisted of a pulmonary vein (PV) isolation (PVI) in patients undergoing an initial AF ablation and in those with PV reconnections after one or more PVI procedures, and additional ablation for non-PV foci and substrate modification for AF including a continuous fractionated atrial electrogram ablation and/ or linear ablation if necessary. During the procedure, a total of four sheaths, three 8-Fr or 8.5-Fr transseptal sheaths (SL0 or Agilis™ NxT, St. Jude Medical, St. Paul, MN, USA) and one 6-Fr sheath for a multielectrode catheter positioned in the coronary sinus (CS), were inserted into the right femoral vein.
A balloon-based PVI using a 28-mm second generation cryoballoon catheter (Arctic Front Advance® cardiac ablation catheter, Medtronic, Minneapolis, MN, USA) or radiofrequency HotBalloon catheter (SATAKE HotBalloon, Toray Industries, Inc., Tokyo, Japan) was performed in patients undergoing an initial AF ablation. If a PVI could not be completed by multiple balloon ablation applications, touch-up ablation for the remaining gaps was performed using an irrigated radiofrequency catheter. A total of three sheaths were inserted into the right femoral vein. During the cryoballoon ablation, Data are given as the mean ± SD, median (IQR), or number of patients (%). BNP, B-type natriuretic peptide; CHADS2 score, congestive heart failure, hypertension, an age ≥75 year, diabetes mellitus (1 point for presence of each), and a stroke and transient ischemic attack (2 points); CHA2DS2-VASc score, congestive heart failure, hypertension, diabetes mellitus, vascular disease (myocardial infarction, aortic plaque, and peripheral vascular disease), an age of 65-74 years, a female gender (1 point for presence of each), an age ≥75 years, and a stroke and transient ischemic attack (2 points); GFR, glomerular filtration rate; HAS-BLED score, hypertension (systolic blood pressure >160 mmHg), abnormal renal and liver function, a stroke, bleeding history/predisposition, labile international normalized ratios (if on warfarin), an age >65 years, drugs (antiplatelets or nonsteroidal anti-inflammatory drugs) or excess alcohol (1 point for presence of each).
Featured Review
Among the 2,193 patients enrolled in this study, 41 (1.9%) had a clinical suspicion of a VTE after the ablation for the following symptoms: leg pain in 17 patients, leg swelling in 16, and both leg pain and swelling in eight. All 41 patients underwent venous ultrasonography, and in addition contrast-enhanced CT and D-dimer testing were performed in nine and six patients, respectively. Symptomatic DVTs after the ablation were noted in two patients (0.091%), who had no predisposing factors of a DVT except for the ablation procedure itself, such as a history of a VTE, malignant neoplasm, or coagulopathy. The clinical characteristics and outcomes of the two symptomatic DVT patients are described in detail as follows, and are summarized in Table 2 . Among the remaining 39 patients undergoing venous ultrasonography, 21 had femoral vascular access complications (11 arteriovenous fistulas, six atrial pseudoaneurysms, and four groin hematomas), and 18 had no obvious complications. One arteriovenous fistula and three atrial pseudoaneurysms required a surgical repair, and the others could be managed by applying local pressure. No symptomatic PTE occurred in this series.
Case 1
A 72-year-old female underwent cryoballoon ablation of paroxysmal AF and received oral anticoagulation with apixaban at a dose of 2.5 mg twice daily. The reduced dose of apixaban was used because two of the three dose reduction criteria (age, ≥80 years; body weight, ≤60 kg; serum creatinine, ≥1.5 mg/dL) were met as follows: body weight, 59 kg and serum creatinine, 1.52 mg/dL. The total procedure time was 111 minutes. Complete hemostasis of the right femoral venous puncture sites was achieved with figure-ofeight sutures, which were removed on the next morning after the procedure. The patient was discharged without any complications on the second post-procedural day.
The patient presented with right leg pain and swelling on the eighth post-procedural day. Duplex ultrasonography and contrast-enhanced CT identified a DVT in the right common femoral vein [ Figure 1 ]. Apixaban was given at a dose of 10 mg twice daily for the first seven days, followed by 5 mg twice daily. Duplex ultrasonography verified the complete disappearance of the thrombi by oral anticoagulation with an increased apixaban dose for 30 days. Neither a DVT recurrence nor bleeding events occurred during the follow-up period.
Case 2
A 74 year old male underwent a radiofrequency HotBalloon ablation of paroxysmal AF and received oral anticoagulation with edoxaban at a dose of 30 mg once daily. The patient's body weight was 43 kg, and a reduced edoxaban dose was used according to the dose reduction criteria (body weight, ≤60 kg). The total procedure time was 101 minutes. Complete hemostasis of the right femoral venous puncture sites was achieved with figure-of-eight sutures, and the patient was discharged on the second post-procedural day.
The patient underwent a second ablation procedure for recurrent one 15-Fr transseptal sheath (FlexCath Advance® Steerable Sheath, Medtronic, Inc.), and two 6-Fr sheaths for multielectrode catheters for CS and phrenic nerve pacing were used. The 6-Fr sheath was exchanged to an 8-Fr transseptal sheath (SL0, St. Jude Medical.) if touch-up ablation was performed. During the radiofrequency Hotballoon ablation, two transseptal sheaths, a 17-Fr steerable sheath (TRESWALTZ, Toray Industries, Inc.) and 8-Fr sheath (SL0, St. Jude Medical.) for a circular mapping catheter, and one 6-Fr sheath for a multielectrode catheter for CS and phrenic nerve pacing, were used.
Diagnosis of Symptomatic VTEs
If patients exhibited clinical signs or symptoms suggesting the presence of a VTE following the ablation procedure, such as pain, swelling, redness, and superficial venous dilatation of the leg, chest pain, and dyspnea, those patients underwent venous ultrasonography, contrast-enhanced computed tomography (CT), and D-dimer testing to evaluate any presence of DVT or PTE.
Statistical Analysis
Normally distributed continuous variables are expressed as the mean ± standard deviation (SD), non-normally distributed continuous variables are expressed as the median and interquartile range (IQR, 25th-75th percentile), and categorical variables are expressed as the number and percentage of patients.
Results
The demographics and baseline characteristics of the study population are summarized in [ Table 1 ]. The age was 64 ± 10 years, percentage of male gender 72.5%, and body mass index (BMI) 23.9 ± 3.5 kg/m 2 . Out of the 2,193 patients, 2,062 patients (94.0%) The ablation procedures and procedure-related data during the first (*) and second (**) ablation procedures, and period from the first (*) and second (**) procedures to the VTE occurrence are shown.
To the best of our knowledge, this is the first report to describe the incidence of symptomatic VTEs in patients who underwent catheter ablation of AF with periprocedural oral anticoagulation using DOACs. We demonstrated that the occurrence of symptomatic DVTs was extremely rare, and no symptomatic PTEs occurred during the periprocedural period of AF ablation under periprocedural DOAC treatment.
The incidence of symptomatic DVTs after AF catheter ablation has been reported to be 0-0.39% in previous retrospective [11] and prospective [12, 15] studies, and is comparable to that of the present study. Those previous studies included patients receiving periprocedural anticoagulation with either warfarin [11, 13] or low-molecular-weight heparin [14, 15] , but no patients received periprocedural anticoagulation with DOACs. Winkle et al. [16] reported that the incidence of PTEs was 0.29% in a retrospective registry with interrupted oral anticoagulation with warfarin.
Factors associated with VTEs
The occurrence of periprocedural VTEs is associated with various factors: the procedure time [17] , bed rest duration [18] , number and size of the sheaths for ablation [17] , periprocedural anticoagulation AF on the 19th day after the first procedure. During the second procedure, the femoral venous punctures were very difficult, but two transseptal sheaths and one 6-Fr sheath were inserted into the right femoral vein. All PVscontinued to be isolated, and an electrical isolation of the superior vena cava (SVC) was performed using an irrigated radiofrequency catheter because AF triggers originating from the SVC were documented. The total procedure time was 77 minutes, and complete hemostasis of the venous puncture sites was achieved with figure-of-eight sutures. The patient was discharged without any complications on the second day after the second procedure.
The patient presented with right leg pain and swelling on the fourth day after the second procedure. Duplex ultrasonography and contrast-enhanced CT identified a DVT in the right common femoral vein [ Figure 2 ]. Edoxaban was changed to rivaroxaban at a dose of 15 mg twice daily for the first 21 days, followed by 15 mg once daily. Duplex ultrasonography verified the complete disappearance of the thrombi after 22 days of oral anticoagulation with rivaroxaban. Neither a DVT recurrence nor bleeding events occurred during the follow-up period. Original Research AF ablation can be useful for detecting venous occlusions [25] , and a reduction in vascular access complications [26] .
Discussion
Periprocedural oral anticoagulation with DOACs may be associated with an extremely low incidence of a VTE. Burstein et al. [2] reported that AF ablation revealed a lower incidence of symptomatic DVTs and PTEs than non-AF ablation, which was likely due to the use of routine periprocedural anticoagulation. In the present study, either of the two anticoagulation protocols were used at the physicians' discretion: uninterruption of the DOACs throughout the periprocedural period or interruption of the DOACs on the procedural day and reinitiation of the DOACs in the next morning after the procedure. The interrupted DOAC protocol was used in both DVT patients, which may have contributed to the DVT occurrence, despite a minimal interrupted period of the DOACs. However, it probably does not seem that the anticoagulation protocol was directly related to the occurrence of the DVT, because the DVT was detected on the fourth and eighth day after reinitiating the DOACs, respectively, for those two patients. regimen [2, 19] and patient characteristics including the age [20] and BMI [18, 21] . AF catheter ablation usually requires multiple venous sheaths inserted into a single femoral vein and a relatively long bed rest duration for hemostasis of the venous puncture sites after the procedure. Several preliminary studies have suggested that injuries to the vascular endothelium caused by the placement of venous sheathsand venous stasis are possible mechanisms for venous thrombus formation [22, 23] . In addition, percutaneous catheter ablation itself is capable of activating the coagulation system, possibly increasing the risk of a thrombosis [19, 24] . Moubarak et al. demonstrated that large sheaths and a long procedure time were risk factors for a DVT after right-sided electrophysiological procedures [17] . The procedure time in the two DVT patients in our study was not so long: 77-111 minutes. On the other hand, 15-Fr and 17-Fr large sheaths for the balloon-based procedures were used in both DVT patients, which may have been a risk for a DVT. In Case 2 of our study, a DVT was detected on the fourth day after the second procedure. However, it is probable that a pre-symptomatic DVT had already occurred after the first HotBalloon ablation procedure, because the right femoral venous punctures were very difficult during the second procedure. Ultrasonographic guidance during the femoral venous puncture for 
Study limitations
The present study had several limitations. First, this single-center study was retrospectively designed, which introduced a sample selection bias. Second, we could not conclude the incidence of a VTE after the AF ablation in this study because the VTEs were not diagnosed based on a rigorous pre-specified protocol of a VTE diagnostic strategy. We performed venous ultrasonography and contrast-enhanced CT only in the patients with symptoms suggesting the presence of a VTE following the ablation procedure. Thus, we may have missed some asymptomatic VTE patients after the ablation, and may have underestimated the incidence of VTEs in patients undergoing AF catheter ablation with periprocedural DOAC treatment. This study focused on the incidence of symptomatic VTEs requiring additional therapeutic intervention. Finally, this study had an extremely low incidence of VTEs. Thus, further understanding of an optimal anticoagulation management for post-ablation VTEs will require an investigation in a prospective study with a larger number of patients in the future.
Conclusion
Periprocedural symptomatic VTEs were an extremely rare occurrence in the patients who underwent catheter ablation of AF and received periprocedural oral anticoagulation with DOACs. Symptomatic DVTs after AF catheter ablation may be adequately treated by increasing the DOAC dose or changing the DOAC type.
